NCT04594213View on ClinicalTrials.gov

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

April 15, 2021

Study Completion Date

May 9, 2022

Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
DRUG

NT 201

Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.

DRUG

Placebo

Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).

Trial Locations (12)

10028

Merz Investigational Site, New York

10065

Merz Investigational Site, New York

10075

Merz Investigational Site, New York

20037

Merz Investigational Site, Washington D.C.

33180

Merz Investigational Site, Aventura

33431

Merz Investigational Site, Boca Raton

37215

Merz Investigational Site, Nashville

70006

Merz Investigational Site, Metairie

80111

Merz Investigational Site, Greenwood Village

91436

Merz Investigational Site, Encino

92121

Merz Investigational Site, San Diego

92663

Merz Investigational Site, Newport Beach

Sponsors

Collaborators (1)

Merz Pharmaceuticals GmbH
All Listed Sponsors
collaborator

Merz Pharmaceuticals GmbH

INDUSTRY

lead

Merz North America, Inc.

INDUSTRY

NCT04594213 - Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines | Biotech Hunter | Biotech Hunter